Chris Nealand
Long only

Durata Therapeutics: Gains Ahead

Durata Therapeutics (NASDAQ:DRTX) is a biotech company focused on the development of novel antibiotics for acute infectious skin diseases. While Durata currently does not produce any revenues, their lead product Dalbavancin will produce significant revenue streams after FDA approval and commercialization.

Dalbavancin is an intravenous antibacterial treatment for acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible Gram-positive bacteria. This once a week two-dose treatment requires only a 30 min peripheral IV consisting of first 1000mgs followed up 8 days later by an additional 500mgs. If approved, Dalbavancin would be the first drug of its type for the treatment ABSSSI.

To put that into comparison, an example of the current process for treating complicated skin...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details